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SUMMARY The aim of this retrospective study was
to evaluate the effect of individually adjusted
custom-made mandibular advancement device/oral
appliance (OA) in treatment of patients with
moderate and severe obstructive sleep apnoea
(OSA), who were non-adherent to continuous
positive airway pressure (CPAP) therapy. During
2007-2013, 116 patients with moderate (n = 82) and
severe (n = 34) OSA non-adherent to CPAP
treatment were referred for dental management
with an individually adjusted OA at a specialist
sleep clinic. Ten of the participants (86%) were
lost to follow-up, leaving the data set to consist of
106 patients (71 men/35 women, mean age 57 year,
range 28-90). Nocturnal respiratory polygraphic
recordings were performed at baseline and follow-
up. Average time between baseline polygraphy and
follow-up was 12 months. A successful OA
treatment outcome was based on polygraphy at
the follow-up and divided into three groups:
1 = AHI <5; 2 = 5 ≤ AHI <10 and >50% reduction in
baseline AHI; and 3. >50% reduction in baseline
AHI. If there was a ≤ 50% reduction in baseline
AHI at the follow-up, the treatment was
considered as a failure. The overall treatment
success rate was 75%. There was no significant
difference in success rates between patients in the
moderate and severe categories (69% and 77%,
respectively). Low oxygen saturation (SpO2 nadir)
had a high predictive value for OA treatment
failure. OA treatment of patients non-adherent to
CPAP is efficient and especially promising for the
severe OSA group who are at greatest risks for
developing serious comorbidities, if left untreated.
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Introduction
Obstructive sleep apnoea (OSA) is a common disor-
der, although prevalence varies widely in the litera-
ture. When using strict diagnostic criteria (full,
attended nocturnal polysomnography), a recent sys-
tematic review reported prevalence among commu-
nity-screened adult patients to range from 2% to
14%. The prevalence varied depending on the cut-off
value of apnoea hypopnoea index (AHI), and for ≥5
events h1 and ≥15/h, the prevalence was 14% and
6%, respectively (1). Similar frequencies have been
found in a large Norwegian population-based study
where the estimated prevalence of OSA was 16% for
AHI ≥ 5 and 8% for AHI ≥ 15 (2).
Patients suffering from moderate and severe OSA
exhibit a range of comorbidities including cardiovas-
cular disease, metabolic syndrome as well as depres-
sion. If their OSA is left untreated, the risk for all-
cause mortality increases (3–6). Continuous positive
airway pressure (CPAP) is a common treatment for
OSA on the basis of its efficacy using objective mea-
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sures (7). Despite its well-known benefits, adherence
is generally poor and its use is often felt bothersome
with little evidence on how its utility might be
improved (8). It has therefore been deemed important
to identify better tolerated treatment options (4).
Oral appliance (OA) treatment has long been used
as measure against snoring and OSA. OA is in general
inferior to CPAP in terms of reducing OSA parameters
based on polygraphy especially in severe OSA. How-
ever, the greater efficacy of CPAP may not necessarily
lead to a superior health outcome compared to treat-
ment with OA. In this regard, it has been reported
that OA adherence is in the range of 76% to 95%,
which exceeds that of CPAP of which vary between
30% and 80% (9, 10). In contrast to CPAP, where
data on adherence can be retrieved from device soft-
ware, adherence to OA is usually self-reported and
less accurate. However, in a recent report where
adherence was measured via a built-in thermistor in
the OA, 1-year results demonstrated a mean use rate
of 64  17 h per night in continuing users and a
regular user rate of 83% (11). Consequently, OA
adherence may actually be higher than for CPAP in
treatment of OSA forming the basis for the suggestion
of similar health outcomes on a group level for the
two treatment modalities (12).
Oral appliance treatment is considered to be equally
effective as CPAP in mild to moderate sleep apnoea, if
titrated sufficiently (12–14). In severe OSA, CPAP is
always the first-line treatment because it has a well-
documented efficacy in reducing apnoeic events. Nev-
ertheless, some studies report promising results even
when using OA in patients with severe OSA (14–16).
In addition, reports on antihypertensive effects and
reduced cardiovascular mortality with OA treatment
indicate a similar outcome to that of CPAP (17, 18).
The major risk groups for health complications
among OSA patients are those with moderate and
especially severe disease. Considering the high non-
adherence rate to CPAP as well as the diverging
results of surgical interventions (19), it is important to
explore other conservative treatment alternatives
more closely.
The aim of this study was to evaluate the effect of
OA treatment in patients with moderate and severe
OSA who were non-adherent to CPAP and to assess
factors predicting treatment success/failure. Our
hypothesis was that OA treatment was superior in
patients with moderate compared to severe OSA.
Materials and methods
The baseline diagnosis of OSA and follow-up investi-
gations were performed by respiratory medicine or
ENT specialists at the Departments of Thoracic Medi-
cine and Otolaryngology at Haukeland University
Hospital, Bergen, Norway, supported by a medical
examination that included home respiratory polygra-
phy (*). Sleep recordings were analysed by experi-
enced respiratory medicine, and ENT specialists and
scoring rules were in accordance with the 2007 Amer-
ican Academy of Sleep Medicine manual (20). The
criteria for mild OSA were AHI 5–149, for moderate
OSA ≥ 15–299 and for severe OSA AHI ≥ 30 (21).
During the years 2007 to 2013, 127 consecutive
patients were identified with a baseline diagnosis of
moderate or severe OSA who had received OA treat-
ment due to non-adherence to CPAP. Non-adherence
to CPAP treatment was defined as less than 5 h
usage/night during a period of at least three months
(22, 23). All OA patients were treated by dentists with
extensive training and experience in Dental Sleep
Medicine.
Within the selected group of OA-treated OSA
patients previously non-adherent to CPAP, inclusion
criteria comprised subjects who had had a sleep study
performed at baseline before CPAP and who attended
the follow-up appointment including new sleep study
using the OA (n = 116). The polygraphy recordings
included AHI, oxygen desaturation index (ODI) and
oxygen saturation parameters: mean (SpO2 mean),
nadir (SpO2 nadir) and percentage time below 90%
(SpO2 <90%). Data on body mass index (BMI), previ-
ous snoring/OSA surgery, smoking habits and comor-
bidities, that is hypertension, other cardiovascular
diseases, diabetes, were retrieved from the patients’
medical records.
Success criteria
A successful OA treatment outcome was based on
polygraphy at the follow-up and divided into three
groups based on the following criteria: 1 = AHI < 5;
2 = 5 ≤ AHI < 10 and more than 50% reduction in
baseline AHI; and 3 = AHI > 50% reduction in base-
*EmblettaTM; ResMed Ltd., Bella Vista, NSW, Australia or NOX-T3;
Nox Medical, Reykjavı´k, Iceland
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line AHI. If there was a ≤ 50% reduction in baseline
AHI at the follow-up, the treatment was considered as
a failure (Table 1).
Oral appliance treatment
Maxillary and mandibular impressions (†) and an
occlusal protrusive wax or silicone index using George
Gauge bite forkTM (‡) were made. The baseline fitting
index of the OA was made at 50–80% of maximum
protrusive capacity. The appliances were custom-
made, and in the majority of patients a dual-block
adjustable type (n = 89) (§) but in a few cases a gen-
eric-type non-adjustable mono-block appliance
(n = 17) was delivered. The latter type of appliance
was in several cases switched to the adjustable type in
order to alleviate titration. Approximately 4–8 weeks
after insertion of the appliance, the first evaluation of
subjective effect was performed, and if not satisfac-
tory, titration of the appliance was carried out. Titra-
tions were performed until the patient reported a
positive subjective effect (e.g. reduced sleepiness/snor-
ing improved sleep) of the OA or until all possible
adjustments were exhausted, after which follow-up
objective overnight polygraphy was carried out.
Statistical analyses
Differences between the moderate and severe OSA
groups and between treatment outcome groups (suc-
cess or failure) were tested by means of the Mann–
Whitney U-test. Wilcoxon signed rank test was used
to analyse intra-individual differences between base-
line and follow-up regarding AHI, ODI and oxygen
saturation parameters. Logistic regression analysis was
performed with the most strict treatment success cri-
teria applied as dependent variable at the follow-up
(success: AHI < 5, failure: AHI ≥ 5). The following cri-
teria were used for selection of independent variables:
(i) theoretical relevance and (ii) significant findings
according to Spearman correlation analysis between
the dependent and the recorded baseline variables.
All independent variables were dichotomized before
entered into the regression model. Unadjusted and
adjusted odds ratios were calculated. Additionally, for-
ward conditional method was applied. Analyses to
account for missing values were performed using mul-
tiple imputations. A P-value less than 005 was con-
sidered statistically significant.
Results
Of the 116 participants, 10 patients (86%) were
lost to follow-up (three died and seven did not
show up for their follow-up appointment). Thus,
the total data set in the study included 106 patients
(71 men, 35 women, mean = 57 year, range 28–90)
who all had both a baseline and a follow-up polyg-
raphy, except for two patients who reported non-
adherence at the follow-up (recorded as failures).
Seventy-four patients were diagnosed as having
moderate OSA, and 32 patients had severe OSA. At
baseline, there were no significant differences
regarding age, BMI, gender, smoking habits and
recorded comorbidities between the two severity
groups (Table 2). Average time between the baseline
sleep study and follow-up was 12 months (range 2–
60 months, s.d. 11).
Baseline and follow-up AHI, ODI and SpO2 parame-
ters (average, nadir and percentage sleep time below
90%) in the two groups are shown in Table 3. The
moderate group showed a significantly lower AHI
(P < 001) and ODI (P = 001) at follow-up compared
to the severe group. The average decrease in AHI
units between baseline and follow-up was 158 and
322 in the moderate and severe group, respectively.
The decrease in AHI units was significantly greater in
the severe compared to the moderate group
(P < 0001). The percentage AHI decrease was how-
ever about the same in both OSA groups; moderate
76% and severe 79%, and not significantly different
Table 1. Criteria for treatment outcome with OA at follow-up
polygraphy
Success
criterion AHI at follow-up
1 AHI < 5
2 5 ≤ AHI < 10 and more
than 50% reduction in baseline AHI
3 >50% reduction in baseline AHI
4 ≤50% reduction in baseline AHI (failure)
AHI, apnoea hypopnoea index.
†Position Penta Quick; 3M ESPE, St Paul, MN, USA
‡Great Lakes Orthodontics, Ltd., Tonawanda, NY, USA
§Somnodent; SomnoMed Ltd., Crows Nest NSW, Australien or
NarvalTM, ResMed Ltd., Bella Vista, NSW, Australia
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between the two groups (Table 4). Self-reported
adherence rate of the OA at the follow-up was 98%
(104/106 patients).
The treatment success rate with the criterion 3
applied (>50% reduction in AHI) was 75% for the
whole group (79/106 patients), comprising 77% and
Table 2. Baseline characteristics of the population studied: age, BMI, gender (males), commenced surgery (for snoring/OSA), smok-
ing (present or previous) and comorbidities (smoking, hypertension, cardiovascular disease, diabetes) in the moderate (n = 74) and
severe (n = 32) OSA groups
Age
(year) (s.d.) BMI (s.d.)
Male
gender, n (%)
Surgery,
n (%)
Smoking,
n (%)
Hypertension,
n (%)
Cardiovascular,
n (%) Diabetes, n (%)
Moderate 57 (120) 282 (42) 46 (62) 32 (43) 27 (37) 34 (46) 13 (18) 8 (11)
NS NS NS NS NS NS NS NS
Severe 57 (122) 295 (43) 25 (78) 18 (56) 13 (41) 18 (56) 7 (22) 1 (3)
NS, not significant; BMI, body mass index.
Table 3. Apnoea hypopnoea index, ODI and oxygen saturation at baseline and follow-up in the moderate (n = 74) and severe
(n = 32) OSA groups
Moderate OSA Severe OSA
AHI
(s.d.)
ODI
(s.d.)
SpO2
mean (s.d.)
SpO2
nadir (s.d.)
SpO2
<90% AHI (s.d.) ODI (s.d.)
SpO2
mean
(s.d.)
SpO2
nadir
(s.d.)
SpO2
<90% (s.d.)
Baseline 212 (40) 174 (80) 93 .4 (15) 800 (59) 80 (93) 414 (99) 351 (142) 928 (25) 768 (48) 191 (178)
*** *** NS ** NS *** *** NS * NS
Follow-up 81 (77) 78 (71) 934 (16) 831 (56) 65 (113) 174 (157) 149 (137) 926 (17) 806 (65) 138 (172)
AHI, apnoea hypopnoea index; ODI, oxygen desaturation index; SpO2 mean, mean oxygen saturation level; SpO2 nadir, lowest oxygen
saturation level; SpO2 <90%, percentage of total sleep time with oxygen saturation level below 90%.
*P < 05; **P < 001; ***P < 0001
Table 4. Apnoea hypopnoea index at follow-up and reduction in AHI units between baseline and follow-up in the moderate and sev-
ere OSA groups divided into successful and failed OA treatment
n Mean Range s.d.
Moderate OSA
Success* AHI at follow-up 57 50 0 to 135 31
Decrease in AHI units 57 158 85 to 290 42
Percentage reduction in AHI between baseline and follow-up 57 76 523 to 1000 138
Failure† AHI at follow-up 15 198 105 to 369 84
Decrease in AHI units 15 22 149 to 114 90
Percentage reduction in AHI between baseline and follow-up 15 8 714 to 479 413
Severe OSA
Success* AHI at follow-up 22 91 0 to 246 72
Decrease in AHI units 22 322 214 to 497 81
Percentage reduction in AHI between baseline and follow-up 22 79 508 to 1000 142
Failure† AHI at follow-up 10 357 175 to 677 137
Decrease in AHI units 10 61 60 to 182 76
Percentage reduction in AHI between baseline and follow-up 10 15 194 to 440 208
AHI, apnoea hypopnoea index.
*Success criteria: 1, 2 or 3.
†Failure criterion: ≤50% reduction in baseline AHI at the follow-up (Table 1).
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69% of the moderate and severe groups, respectively.
AHI < 5 (criterion 1) was recorded in 43% of patients
in the moderate and 25% in the severe group, while
it was 38% for both groups together. The combined
figures for criteria 1 and 2 (5 ≤ AHI < 10 and more
than 50% reduction in baseline AHI) were 70% and
50%, for the moderate and severe groups respectively.
There was no significant difference in treatment out-
come between the moderate and severe groups using
the above-mentioned success criteria (Fig. 1). AHI at
baseline and at follow-up after OA treatment in the
successful group (criterion 1, 2 or 3, n = 79) and in
the failure group (≤ 50% reduction in baseline AHI at
follow-up, n = 25) for each participant is shown in
Fig. 2a and b.
In bivariate analyses between treatment outcome
(success or failure) and baseline parameters, the suc-
cess group, including both moderate and severe OSA,
had lower prevalence of cardiovascular disease
(P < 005), and a tendency for lower age and BMI
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Fig. 1. Comparison between moderate (n = 74) and severe
(n = 32) groups according to success criteria applied after treat-
ment with oral appliance at follow-up.
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Fig. 2. (a) Apnoea hypopnoea
index at baseline and at follow-up
after OA treatment in the successful
group (criterion 1, 2 or 3 according
to Table 1, n = 79). Patients are
ordered from high to low baseline
AHI. (b) AHI at baseline and at
follow-up after OA treatment in the
failure group (≤50% reduction in
baseline AHI at follow-up according
to Table 1, n = 25). Patients are
ordered from high to low baseline
AHI.
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(P = 0075 and P = 005, respectively). Baseline AHI
or gender did not differ between success and failure
groups.
The outcome on the univariate evaluation of factors
potentially predicting treatment failure is shown in
Table 5, and the results from the logistic regression
analyses are presented in Table 6. In the unadjusted
analyses, all selected independent variables, except
gender and SpO2 <90%, were significantly correlated to
the success criteria applied, while in the fully adjusted
analyses none of the variables predicted treatment
failure/success. When applying the forward condi-
tional method, SpO2 nadir turned out to be significant
(OR = 036, p = 0001) (Table 6); Nagelkerke R2 was
018 and the sensitivity (correctly classified success-
fully treated) and specificity (correctly classified fail-
ures) was 37% and 93%, respectively. The predicted
probability for all variables and for SpO2 nadir is illus-
trated by the receiver operating characteristic (ROC)
curve where the area under the curve (AUC) was
066 for SpO2 nadir while AUC for all the variables
combined was 079 (Fig. 3).
The 10 patients lost to follow-up did not differ sig-
nificantly compared to those who completed the
study regarding age, gender, BMI, diagnosis (severe or
moderate OSA), baseline AHI/ODI, snoring/OSA sur-
gery, smoking habits, hypertension/cardiovascular dis-
eases and diabetes.
Discussion
This retrospective study of 106 moderate and severe
OSA patients non-adherent to CPAP showed an
overall success rate of 75% using the criterion 3 (>
50% reduction in baseline AHI) (Table 1). This suc-
cess rate compares favourably with that reported in
recent reviews (9, 24), although most previous stud-
ies only included patients with mild to moderate
OSA. Using the success criteria applied in this study,
comparison of treatment outcome between the mod-
erate and severe group showed no significant differ-
ences, albeit that a numerically higher proportion of
patients reached AHI < 5 in the moderate group.
What constitutes clinically acceptable success criteria
for OSA treatment is much debated (9, 25).
Although the moderate group had a significantly
lower AHI (mean = 5) compared to the severe
group (mean = 9) at follow-up, the latter experi-
enced a considerably higher decrease in AHI units
compared to the former (32 vs. 16 units). The clini-
cal implication of this is unclear, but one may spec-
ulate that such a dramatic decrease of apnoeic
events in the severe group may have a positive
impact on health status even if not reaching the
level of AHI < 5.
In category 2 success, it was required a 50% reduc-
tion in baseline AHI in addition to be below AHI 10
at follow-up. The reason for refinement of the criteria
was that it was desired not only to appraise the cut-
off point of 10 but also to make sure that the reduc-
tion had the commonly stated opinion that a 50%
reduction in baseline AHI has a clinical benefit in the
treatment of sleep apnoea patients (Table 1). There
are only a few studies reporting on OA treatment of
severe OSA. In this regard, and using similar criteria
(> 50% reduction in baseline AHI) and follow-up
time as in the present study, severe OSA treated with
OA showed 44% (26) and 58% (14) success at 1-year
follow-up. The higher success rate in this study (67%)
may have several explanations, for example study
design (retrospective study bias) and participant selec-
tions. When the most strict treatment success criteria
Table 5. Correlations between success (AHI <5 at follow-up,
n = 40) or failure (AHI ≥ 5 at follow-up, n = 66) and back-
ground variables and their dichotomizations
Baseline variables Dichotomization
Success AHI <5
R P
Gender Man 007 05 (NS)
Woman
Age ≤69 year
>69 year 020 004
BMI <275
≥275 023 002
AHI 15–25
> 25 020 004
ODI ≤20
>20 033 0001
SpO2 nadir <85% 038 0001
≥85%
SpO2 <90% ≥10% 024 004
<10%
Cardiovascular/
diabetes disease
No
Yes 026 0007
R, Spearman’s rho; P, significance level; AHI, apnoea hypopnoea
index; ODI, oxygen desaturation index; SpO2 mean, mean oxy-
gen saturation level; SpO2 nadir, lowest oxygen saturation level;
SpO2 <90%, percentage of total sleep time with oxygen saturation
level below 90%.
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were applied (AHI<5 at follow-up polygraphy), a
number of baseline variables were significantly corre-
lated to success in the unadjusted regression model.
The anthropometric and polygraphic variables which
have been reported as good predictors of successful
OA treatment (9) are affirmative to those found in
our unadjusted regression analyses (Table 6). In the
adjusted model, none of the included variables
turned out to be significant which may be explained
of the inherent cross-correlations that exist between
them and a reduced power in the analyses due to
many variables in the model. However, in the final
model (using the forward conditional method), only
SpO2nadir remained in the model with OR 036
demonstrating a low sensitivity (40%) but a high
specificity (93%). It has been stated that more
research is needed to define the patients who will
benefit from MAD treatment (9) and it would also be
of significance to identify those who do not. Interpre-
tation of the findings from the regression analyses
may be that low oxygen saturation in OSA is an
important predictor for OA failure in patients non-
adherent to CPAP. This preliminary finding needs to
be corroborated in future studies.
Patient categories with deep oxygen desaturations
in conjunction with breathing cessations are typically
those with pre-existing chronic diseases of the chest
affecting gas exchange, such as chronic obstructive
pulmonary disease (COPD), congestive heart failure
and pulmonary hypertension. There is good evidence
that oxygenation deficits rather than breathing cessa-
tions per se predicts mortality in patients with OSA
(27). Furthermore, survival effects of positive airway
pressure treatment in patients with OSA with chronic
lung disease are documented (28), whereas research
on OA treatment outcomes in COPD is lacking. The
Table 6. Logistic regression analysis and associations between failure and success of OA treatment at follow-up (dependent variable:
1 = failure AHI ≥ 5; 2 = success, AHI < 5) and selected independent variables for unadjusted, adjusted and forward conditional models
(Forward)
Independent variables Unadjusted OR (CI) P Adjusted OR (CI) P Forward OR (CI)† P
Gender
Man = 1 073 (032–167) 045 074 (026–21) 057 *
Woman = 2
Age
≤69 year = 1 67 (086–566) 007 98 (092–104) 006 *
>69 year = 2
BMI
<275 = 1 26 (11–59) 002 21 (075–61) 016 *
≥275 = 2
AHI baseline
15–25 = 1 23 (10–53) 004 067 (019–24) 054 *
>25 = 2
ODI baseline
≤20 = 1 41 (17–99) 0001 28 (073–110) 013 *
>20 = 2
SpO2 nadir
<85% = 1 015 (004–054) 0004 030 (007–13) 010 † 0001
≥85% = 2
SpO2 <90%
≥10% = 1 036 (012–11) 007 073 (020–27) 063 *
<10% = 2
Cardiovascular or diabetes disease
No = 1 30 (13–68) 0008 012 (0005–21) 014 *
Yes = 2
OR, odds ratios; CI, 95% confidence intervals; P, significance level; Forward, forward conditional method; AHI, apnoea hypopnoea
index; ODI, oxygen desaturation index; SpO2 mean, mean oxygen saturation level; SpO2 nadir = lowest oxygen saturation level; SpO2
<90% = percentage of total sleep time with oxygen saturation level below 90%.
*Variable excluded in the final model.
†Variable included in the final model
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current results therefore support treatment with posi-
tive airway pressure methods, rather than OA treat-
ment, in patients with severe oxygen desaturations
from the diagnostic sleep studies, independent of OSA
severity judged by the AHI only. However, it has to
remembered that all participants where PAP-non-
adherent and findings may not be generalized to the
treatment decisions in treatment-naive patients with
OSA.
Our definition of PAP non-adherence (less than 5 h
per night over 3 months treatment) is based on publi-
cations demonstrating clinical meaningful responses
on sleepiness, daily functioning and reductions in
blood pressure in patients achieving at least 5–6 h
adherence to CPAP per night (22, 23). In the current
study, all participants have been treated with auto-
CPAP devices, which automatically adjust the deliv-
ered pressures needed to avoid breathing cessations.
No patients have been manually titrated in an over-
night laboratory setting. Subjects with large desatura-
tions at initial sleep study, who should be encouraged
to PAP treatment despite adherence problems, could,
when other causes of non-adherence have been
excluded, undergo manually PAP titration in a sleep
laboratory to ensure better treatment tolerance. In
cases of CPAP non-adherence, other forms of pressure
support such as bilevel or adaptive servo-ventilation
are often better accepted by subjects with chronic
heart and lung disease.
The drawbacks of this study are several, and maybe
the largest weakness is that we did not obtain ade-
quate data related to subjective outcome of the treat-
ment. Epworth Sleepiness Scale was recorded, but not
consistently so in all instances. Details of adherence,
such as number of nights and total hours of usage, to
OA treatment was neither assessed which is another
weakness but of the total of 116 patients who were
prescribed OA treatment only two were recorded as
non-adherent at the follow-up. Patients non-adherent
to CPAP treatment are found to exhibit many barriers
against its usage (29), and some of these may well be
applicable to the use of an OA as well, although was
apparently not so considering the seemingly high self-
reported adherence of 98%.
Considering that the enrolled patients in this study
were failures with the gold standard treatment for
OSA (CPAP), we conclude that our results are very
promising and especially so for severe OSA patients
who are at greatest risks for serious medical conse-
quences, if untreated. Low oxygen saturation (SpO2
nadir) had a high predictive value for OA treatment
failure irrespective of baseline AHI. Limited to the
success criteria applied and to our surprise, the
hypothesis that OA treatment is superior in patients
with moderate compared to severe OSA was rejected.
Future prospective and well-designed studies are war-
ranted in order to confirm the findings from this
study.
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